GRI Bio, Inc. Common Stock (GRI) is a publicly traded Healthcare sector company. As of May 21, 2026, GRI trades at $2.23 with a market cap of $3.09M and a P/E ratio of -0.02. GRI moved -0.45% today. Year to date, GRI is -74.50%; over the trailing twelve months it is -94.58%. Its 52-week range spans $1.97 to $852.04. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces GRI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GRI Bio CEO Highlights Phase 2a IPF Biomarker Gains in Fibrosis and Lung Repair: GRI Bio CEO Marc Hertz detailed additional positive Phase 2a data in idiopathic pulmonary fibrosis, highlighting biomarker improvements in key drivers of fibrosis and lung repair. The company emphasized these results during a Virtual Investor “What This Means” segment to reinforce the potential of its lead oral NKT cell modulator, GRI-0621.
| Metric | Value |
|---|---|
| Price | $2.23 |
| Market Cap | $3.09M |
| P/E Ratio | -0.02 |
| EPS | $-121.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $852.04 |
| 52-Week Low | $1.97 |
| Volume | 50 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.96M |
| Gross Margin | 0.00% |
2 analysts cover GRI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.